A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, single-arm study in patients with stage IIIB (with malignant pleural
effusion) and IV NSCLC who have been previously treated with a platinum-based doublet.
Each cycle will be 21 days. On Day 1 of each cycle, patients will receive vinflunine 320
mg/m2 as a 20-minute IV infusion.
Patients will continue to receive study treatment until disease progression or unacceptable
toxicity.
Patients will be evaluated every 2 cycles for response using RECIST criteria.